Home > Insider Trading > Filing (0001209191-19-047723)

Filing Details

Accession Number:: 0001209191-19-047723
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-08-29 16:59:51
Reporting Period:: 2019-08-27

Accepted Time:: 2019-08-29 16:59:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1108109	Community Health Systems Inc	CYH	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1018660	T Wayne Smith	4000 Meridian Boulevard Franklin TN 37067	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-08-27	495,600	$1.84	3,132,082	No	4	P	Direct
Common Stock	Acquisiton	2019-08-28	489,250	$2.05	3,621,332	No	4	P	Direct
Common Stock	Acquisiton	2019-08-29	215,150	$2.18	3,836,482	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	206,842	Indirect	by 2009 WTS Irrevocable Trust Dated 2/27/09
Common Stock	481,721	Indirect	WAC LLC

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (Right to Buy)	$30.32	2011-02-24	2020-02-23	50,000	50,000	Direct
Common Stock	Stock Options (Right to Buy)	$34.38	2012-02-23	2021-02-22	50,000	50,000	Direct
Common Stock	Stock Options (Right to Buy)	$17.49	2013-02-16	2022-02-15	40,000	40,000	Direct
Common Stock	Stock Options (Right to Buy)	$4.99	2020-03-01	2029-02-28	78,750	78,750	Direct
Common Stock	Performance Based Restricted	$0.00			75,000	75,000	Direct
Common Stock	Performance Based Restricted	$0.00			105,000	105,000	Direct
Common Stock	Performance Based Restricted	$0.00			157,500	157,500	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2020-02-23	50,000	50,000	Direct
2021-02-22	50,000	50,000	Direct
2022-02-15	40,000	40,000	Direct
2029-02-28	78,750	78,750	Direct
	75,000	75,000	Direct
	105,000	105,000	Direct
	157,500	157,500	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/27/2019 at prices ranging from $1.80 to $1.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (1), (2) and (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/28/2019 at prices ranging from $1.87 to $2.14, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on 8/29/2019 at prices ranging from $2.12 to $2.20, inclusive.
The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2017 and 12/31/2019 (the "2017-2019 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2017-2019 Performance Period.
The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2018 and 12/31/2020 (the "2018-2020 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2018-2020 Performance Period.
The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2019 and 12/31/2021 (the "2019-2021 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2019-2021 Performance Period.